Home LiteratureArticle Details
PMID: 11122802 Published · ppublish English Journal Article Review

In vitro chemosensitivity testing and mechanisms of drug resistance.

Current oncology reports ·Vol. 1 ·No. 1 ·1999-09-00 ·Pages 77-84

Tewari K, Manetta A

Abstract

This article reviews the cellular mechanisms that confer biochemical and clinical resistance to antineoplastic agents used in the adjunctive treatment and palliation of metastatic ovarian cancer. The historical development of in vitro chemosensitivity testing is also reviewed, along with published experiences of various investigators with assays used in clinical ovarian cancer treatment programs. Finally, an investigational protocol for chemosensitivity testing is proposed.

MeSH Terms
Drug Resistance, Neoplasm Drug Screening Assays, Antitumor/methods Female Humans Ovarian Neoplasms/drug therapy Sensitivity and Specificity
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Tewari K
Division of Oncology, Chao Family Comprehensive Cancer Center, University of Califorinia, Irvine Medical Center, 101 The City Drive, Orange, CA 92868, USA.
Manetta A
References (49)
49 references, click to expand
  1. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    J Natl Cancer Inst. 1993 Nov 3;85(21):1732-42 PMID: 8411257
  2. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid.
    Cancer Res. 1991 Nov 15;51(22):6059-65 PMID: 1933869
  3. Tumor chemosensitivity and chemoresistance assays.
    Cancer. 1997 Apr 1;79(7):1447-50 PMID: 9083168
  4. Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.
    Med Biol. 1984;62(6):338-43 PMID: 6543460
  5. Tumor chemosensitivity and chemoresistance assays.
    Cancer. 1996 Mar 15;77(6):1020-5 PMID: 8635118
  6. Depletion of glutathione in normal and malignant human cells in vivo by buthionine sulfoximine: clinical and biochemical results.
    J Natl Cancer Inst. 1992 Feb 19;84(4):264-7 PMID: 1734088
  7. Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
    J Clin Oncol. 1987 Apr;5(4):641-7 PMID: 3559654
  8. Review of the efficacy of individualized chemotherapy selected by in vitro drug sensitivity testing for patients with cancer.
    J Clin Oncol. 1999 May;17(5):1625-31 PMID: 10334552
  9. Further observations on the effects of cancer chemotherapeutic agents on the in vitro dehydrogenase activity of cancer tissue.
    J Natl Cancer Inst. 1954 Apr;14(5):1147-58 PMID: 13233851
  10. The clinical relevance of chemosensitivity testing in ovarian cancer.
    Cancer Detect Prev. 1998;22(4):305-12 PMID: 9674873
  11. A Southwest Oncology Group study on the use of a human tumor cloning assay for predicting response in patients with ovarian cancer.
    Cancer. 1991 Jan 1;67(1):20-7 PMID: 1985717
  12. Highly specific prediction of antineoplastic drug resistance with an in vitro assay using suprapharmacologic drug exposures.
    J Natl Cancer Inst. 1990 Apr 4;82(7):582-8 PMID: 2313735
  13. Drug resistance in ovarian cancer: from the laboratory to the clinic.
    Obstet Gynecol. 1998 Aug;92(2):312-9 PMID: 9699774
  14. Action of x-rays on mammalian cells.
    J Exp Med. 1956 May 1;103(5):653-66 PMID: 13319584
  15. Development of a miniaturized, improved nucleic acid precursor incorporation assay for chemosensitivity testing of human solid tumors.
    Cancer Res. 1985 Nov;45(11 Pt 1):5436-41 PMID: 4053017
  16. Expression of P-glycoprotein in epithelial ovarian cancer: evaluation as a marker of multidrug resistance.
    Am J Obstet Gynecol. 1990 Jul;163(1 Pt 1):69-73 PMID: 1973872
  17. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma.
    Cancer Res. 1995 Nov 15;55(22):5276-82 PMID: 7585588
  18. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
    Cancer Res. 1993 Nov 1;53(21):5225-32 PMID: 8106143
  19. Glutathione S-transferases: role in alkylating agent resistance and possible target for modulation chemotherapy--a review.
    Cancer Res. 1990 Oct 15;50(20):6449-54 PMID: 2208103
  20. Prediction of drug resistance in cancer chemotherapy: the Kern and DiSC assays.
    Oncology (Williston Park). 1991 Sep;5(9):93-103; disc. 104, 111-4, 117-8 PMID: 1835882
  21. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors.
    Cancer Res. 1983 Feb;43(2):749-57 PMID: 6184155
  22. p53-dependent apoptosis suppresses tumor growth and progression in vivo.
    Cell. 1994 Aug 26;78(4):703-11 PMID: 8069917
  23. Chemosensitivity testing in ovarian cancer.
    Cancer. 1993 Feb 15;71(4 Suppl):1613-20 PMID: 8431897
  24. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents.
    Cell. 1993 Sep 24;74(6):957-67 PMID: 8402885
  25. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
    Proc Natl Acad Sci U S A. 1987 Nov;84(21):7735-8 PMID: 2444983
  26. Use of the extreme drug resistance assay to evaluate mechanisms of resistance in ovarian cancer: taxol resistance and MDR-1 expression.
    Contrib Gynecol Obstet. 1994;19:39-52 PMID: 7995052
  27. In vitro determination of cytotoxic drug response in ovarian carcinoma using the fluorometric microculture cytotoxicity assay (FMCA).
    Int J Cancer. 1997 Sep 17;72(6):1008-12 PMID: 9378534
  28. Ovarian carcinoma cells in culture: assessment of drug sensitivity by clonogenic assay.
    Br J Cancer. 1984 Sep;50(3):317-26 PMID: 6540594
  29. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines.
    Biochem Pharmacol. 1994 Feb 11;47(4):689-97 PMID: 8129746
  30. Tumor heterogeneity and in vitro chemosensitivity testing in ovarian cancer.
    Am J Obstet Gynecol. 1997 Apr;176(4):759-66; discussion 766-8 PMID: 9125599
  31. Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing.
    Gynecol Oncol. 1988 Sep;31(1):191-204 PMID: 3410347
  32. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays.
    J Immunol Methods. 1983 Dec 16;65(1-2):55-63 PMID: 6606682
  33. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
    N Engl J Med. 1996 Jan 4;334(1):1-6 PMID: 7494563
  34. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.
    N Engl J Med. 1978 Jun 15;298(24):1321-7 PMID: 77475
  35. Antineoplastic drug resistance and DNA repair.
    Ann Oncol. 1991 May;2(5):325-34 PMID: 1954176
  36. Chemosensitivity testing of fresh human leukemia cells using both a dye exclusion assay and a tetrazolium dye (MTT) assay.
    Leuk Res. 1990;14 (5):459-66 PMID: 2345469
  37. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair.
    J Biol Chem. 1994 Jan 14;269(2):787-90 PMID: 8288625
  38. Mitoxantrone combined with paclitaxel as salvage therapy for platinum-refractory ovarian cancer: laboratory study and clinical pilot trial.
    Clin Cancer Res. 1997 Sep;3(9):1527-33 PMID: 9815839
  39. Chemotherapy of ovarian cancer directed by the human tumor stem cell assay.
    Cancer Chemother Pharmacol. 1981;6(3):279-85 PMID: 6172215
  40. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
    Semin Cancer Biol. 1991 Aug;2(4):235-44 PMID: 1655118
  41. Selection of cancer chemotherapy for a patient by an in vitro assay versus a clinician.
    J Natl Cancer Inst. 1990 Jan 17;82(2):110-6 PMID: 2403593
  42. Primary bioassay of human tumor stem cells.
    Science. 1977 Jul 29;197(4302):461-3 PMID: 560061
  43. Cell biological markers of drug resistance in ovarian carcinoma.
    Gynecol Oncol. 1995 Aug;58(2):165-78 PMID: 7622101
  44. Direct cloning of human ovarian carcinoma cells in agar.
    Cancer Res. 1978 Oct;38(10):3438-44 PMID: 210939
  45. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.
    BMJ. 1991 Oct 12;303(6807):884-93 PMID: 1834291
  46. A feasibility study of the MTT assay for chemosensitivity testing in ovarian malignancy.
    Br J Cancer. 1990 Aug;62(2):189-94 PMID: 2386733
  47. Individual human tumors in short-term micro-organ cultures: chemosensitivity testing by fluorescent cytoprinting.
    In Vitro Cell Dev Biol. 1988 Nov;24(11):1137-46 PMID: 3192508
  48. Combination chemotherapy tested in a short-term thymidine incorporation assay in primary cultures of ovarian adenocarcinomas.
    Int J Cell Cloning. 1992 May;10(3):182-9 PMID: 1613269
  49. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.
    J Clin Oncol. 1991 Sep;9(9):1668-74 PMID: 1831495
Article Info
Journal
Current oncology reports
Abbr.
Curr Oncol Rep
ISSN
1523-3790
DOI
10.1007/s11912-999-0014-6
Published
1999-09-00
Pages
77-84
Language
English
Region
United States
NLM ID
100888967
Subset
IM
External Links
PubMed source DOI: 10.1007/s11912-999-0014-6 View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2